Humanwell Healthcare Obtains Abbreviated New Drug Application Approval from US FDA for Nintedanib
() -- Humanwell Healthcare (SHA:600079) subsidiary Humanwell Pukang Pharmaceutical (Wuhan) received an abbreviated new drug application approval from the U.S. Food and Drug Administration for its nintedanib, according to a Shanghai Stock Exchange filing on Saturday. The drug is indicated for idiopathic pulmonary fibros